180-Day Exclusivity: How Patent Challenges Delay Generic Drug Entry
The 180-day exclusivity rule under the Hatch-Waxman Act gives the first generic drug challenger a monopoly on the market-but it often delays competition for years. Here’s how it works, who benefits, and why patients pay more.
Continue Reading